XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Research and License Agreements - Additional Information (Detail) (USD $)	3 Months Ended	1 Months Ended	3 Months Ended		1 Months Ended	3 Months Ended	130 Months Ended
	Mar. 31, 2014	Oct. 31, 2011 Pfizer License Agreement [Member]	Mar. 31, 2014 Pfizer License Agreement [Member]	Mar. 31, 2013 Pfizer License Agreement [Member]	Oct. 31, 2011 Up-Front Payment Arrangement [Member] Pfizer License Agreement [Member]	Mar. 31, 2013 Up-Front Payment Arrangement [Member] Pfizer License Agreement [Member]	Mar. 31, 2014 Up-Front Payment Arrangement [Member] Pfizer License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Owed percentage of payment to the University for future milestone and royalty	10.00%
Received up-front payment on execution of agreement					$ 22,500,000	$ 3,800,000	$ 22,500,000
Potential milestone payments upon the achievement of specified development milestones		115,000,000
Potential milestone payments upon the achievement of specified regulatory milestones		70,000,000
Potential milestone payments upon the achievement specified levels of annual net sales of licensed products		135,000,000
Potential milestone payment to be received under the agreement		35,000,000
Advance payment against milestone payment		15,000,000
Period of up-front payment				1 year 6 months
Earned or recognized milestone			$ 0

X

- Definition

Maximum milestone payment upon achievement of dosing of first patient in phase three clinical trials.

+ References

No definition available.

+ Details

Name:	glyc_MaximumMilestonePaymentUponAchievementOfDosingOfFirstPatientInPhaseThreeClinicalTrials
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum milestone payment upon achievement of specified development milestone.

+ References

No definition available.

+ Details

Name:	glyc_MaximumMilestonePaymentUponAchievementOfSpecifiedDevelopmentMilestone
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum milestone payment upon achievement of specified levels of annual net sales of licensed products.

+ References

No definition available.

+ Details

Name:	glyc_MaximumMilestonePaymentUponAchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProducts
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum milestone payment upon achievement of specified regulatory milestone.

+ References

No definition available.

+ Details

Name:	glyc_MaximumMilestonePaymentUponAchievementOfSpecifiedRegulatoryMilestone
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Milestone payment expected receivable.

+ References

No definition available.

+ Details

Name:	glyc_MilestonePaymentExpectedReceivable
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Owed percentage of future milestone and royalty payment.

+ References

No definition available.

+ Details

Name:	glyc_OwedPercentageOfFutureMilestoneAndRoyaltyPayment
Namespace Prefix:	glyc_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Upfront payment recognition period.

+ References

No definition available.

+ Details

Name:	glyc_UpfrontPaymentRecognitionPeriod
Namespace Prefix:	glyc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration